Resources library

Late-Stage Capabilities One Pager

Learn how OXB supports the transition from late-stage development to commercial supply through proven expertise in process characterisation, PPQ, regulatory submissions and commercial-scale GMP manufacturing.

Isolating T-Cell Potent Lentiviral Vector Subpopulations through Rational Design of Nanofiber Anion-Exchange Adsorbents

This paper investigates lentiviral vector heterogeneity during anion-exchange chromatography and identifies a nanofiber-based purification approach that enhances recovery and separation of high-potency vectors.

In vivo CAR‑T – Reimagining Immune Engineering with Direct Cell Reprogramming

An overview of the opportunities and challenges of in vivo CAR-T therapy, including the technologies that could transform how next-generation cell therapies are delivered to patients. Published in The Medicine Maker.

Efficient In Vivo Generation of CAR T Cells using a Retargeted Fourth-Generation Lentiviral Vector

Infographic: The 7 Regulatory Milestones Every Viral Vector Developer Should Plan For

A practical visual roadmap outlining the seven key regulatory milestones viral vector developers should consider from early development through lifecycle management.

5 Questions with… Melanie Kearney

Quality is about more than compliance. It's about building confidence at every stage of development. In this edition of 5 Questions with..., Dr. Melanie Kearney, SVP, Global Head of Quality at OXB, explores why Quality should be embedded from the very beginning of a cell and gene therapy programme.